{
  "example": {
    "id": "statistical_analysis_oncology",
    "title": "Statistical Analysis and Data Interpretation",
    "subtitle": "Mid-course analysis of oncology biomarker trial with mixed efficacy signals",
    "duration": "12-15 minutes",
    "category": "Data Analysis & Biomarker Development",
    
    "hero": {
      "title": "Clinical Trial Data Analysis Intelligence",
      "lead": "See how AI-assisted reasoning transforms complex interim analysis decisions",
      "timeInvestment": "12-15 minutes ‚Ä¢ Real oncology trial scenario ‚Ä¢ Statistical analysis focus"
    },
    
    "credibility": {
      "expertise": "Developed with biostatisticians from Genentech, Roche, and leading oncology biotechs",
      "dataSource": "Based on analysis of 25+ Phase II oncology biomarker trials and FDA guidance"
    },
    
    "persona": {
      "name": "Dr. Marcus Rodriguez",
      "title": "Chief Medical Officer",
      "company": "Series B oncology biotech developing novel CDK4/6 inhibitor",
      "background": "15 years oncology drug development, former Genentech",
      "challenge": "Phase II trial showing mixed results, needs data interpretation for go/no-go decision"
    },
    
    "scenario": {
      "title": "Oncology Biomarker Trial Mid-Course Analysis",
      "description": "Phase II dose-finding study showing mixed efficacy signals across dose levels and biomarker subgroups",
      "context": {
        "study": "Phase II CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer",
        "status": "85 patients enrolled (target 120), interim analysis at 60 patients completed",
        "challenge": "23% ORR overall with significant differences between dose levels and biomarker subgroups"
      }
    },
    
    "steps": [
      {
        "stepNumber": 1,
        "title": "Statistical Analysis Planning",
        "userInput": {
          "type": "user-input",
          "speaker": "Dr. Rodriguez",
          "content": "I need help interpreting our interim analysis results for our CDK4/6 inhibitor trial. We're seeing 23% ORR overall but big differences between dose levels and some interesting biomarker patterns. I want to understand if we should modify our enrollment strategy, adjust dose levels, or how to position this data for the FDA."
        },
        "systemAnalysis": {
          "type": "system-analysis",
          "title": "System Initial Analysis",
          "bullets": [
            "**Trial Type Recognition:** Phase II oncology biomarker study with interim analysis",
            "**Statistical Context:** 60/120 patients analyzed, ORR primary endpoint",
            "**Historical Benchmarks:** Previous CDK4/6 inhibitor trials (PALOMA-3, MONALEESA-3, MONARCH-2)",
            "**Regulatory Context:** FDA oncology guidance for biomarker-driven development",
            "**Key Analysis Areas:** Dose-response relationship, biomarker stratification, sample size adequacy"
          ]
        },
        "reasoning": {
          "title": "How did the system analyze the interim results?",
          "steps": [
            "**Study Design Mapping:** Maps trial to oncology biomarker study ontology, identifies comparable historical trials",
            "**Statistical Framework Activation:** Engages statistical analysis agents for interim analysis interpretation, dose-response modeling",
            "**Regulatory Pathway Assessment:** Analyzes results against FDA guidance for oncology biomarker studies",
            "**Historical Performance Comparison:** Benchmarks 23% ORR against historical CDK4/6 inhibitor studies",
            "**Decision Tree Preparation:** Prepares multiple pathway options based on statistical interpretations"
          ]
        },
        "feedback": {
          "question": "How do you typically handle interim analysis decisions with mixed efficacy signals?",
          "options": [
            "Collaborative team analysis",
            "External statistical consultants", 
            "Principal investigator judgment",
            "This is a challenge for us"
          ]
        }
      },
      
      {
        "stepNumber": 2,
        "title": "Multi-Agent Statistical Analysis",
        "systemAnalysis": {
          "type": "system-analysis",
          "title": "Coordinated Agent Analysis Results",
          "agents": [
            {
              "icon": "üìä",
              "name": "Statistical Analysis Agent",
              "result": "23% ORR at interim (n=60) suggests potential efficacy signal; confidence interval 13-35% indicates need for larger sample"
            },
            {
              "icon": "üß¨",
              "name": "Biomarker Stratification Agent", 
              "result": "Strong signal in PIK3CA wild-type patients (35% ORR, n=25) vs. PIK3CA mutant (12% ORR, n=35)"
            },
            {
              "icon": "üíä",
              "name": "Dose-Response Agent",
              "result": "Clear dose-response: 300mg (18% ORR), 450mg (28% ORR), 600mg (25% ORR with toxicity)"
            },
            {
              "icon": "‚öñÔ∏è",
              "name": "Regulatory Strategy Agent",
              "result": "Results support biomarker-driven registration; PIK3CA stratification enables accelerated approval pathway"
            },
            {
              "icon": "üìà",
              "name": "Power Analysis Agent",
              "result": "70% power for overall population, 85% power for PIK3CA wild-type subgroup with full enrollment"
            }
          ]
        },
        "reasoning": {
          "title": "How do multiple AI agents coordinate statistical analysis?",
          "steps": [
            "**Multi-Dimensional Integration:** Coordinates statistical, biomarker, dose-response, and regulatory agents",
            "**Historical Benchmarking:** Compares results against 15 similar oncology biomarker trials",
            "**Biomarker Effect Calculation:** Uses PIK3CA data to calculate biomarker-specific effect sizes",
            "**Dose Optimization Modeling:** Applies modeling to identify optimal dose balancing efficacy/safety",
            "**Regulatory Pathway Mapping:** Maps results to FDA biomarker guidance for registration strategy"
          ]
        },
        "dataVisualization": {
          "title": "Statistical Analysis Summary",
          "chartType": "biomarker_stratification",
          "data": "Overall ORR: 23% | PIK3CA Wild-type: 35% | PIK3CA Mutant: 12% | Optimal Dose: 450mg (28% ORR)"
        },
        "feedback": {
          "question": "Have you seen similar biomarker effects that changed your development strategy?",
          "options": [
            "Yes, biomarkers often reshape our trials",
            "Sometimes, but we're cautious about subgroups",
            "Rarely modify based on biomarker signals",
            "We avoid biomarker-driven development"
          ]
        }
      },
      
      {
        "stepNumber": 3,
        "title": "Strategic Recommendations for Trial Modification",
        "systemRecommendations": {
          "type": "system-recommendations",
          "title": "Optimized Development Strategy Options",
          "options": [
            {
              "icon": "üéØ",
              "name": "Biomarker-Driven Pivot",
              "strategy": "Modify enrollment to focus on PIK3CA wild-type patients only",
              "sampleSize": "75 additional wild-type patients needed",
              "timeline": "+6 months for biomarker screening and targeted recruitment",
              "advantage": "35% ORR in wild-type provides stronger regulatory position"
            },
            {
              "icon": "üöÄ", 
              "name": "Dose Optimization Path",
              "strategy": "Continue current enrollment, focus on 450mg dose level",
              "sampleSize": "Complete planned enrollment (60 additional patients)",
              "timeline": "On track for completion in 8 months",
              "risk": "Overall population may not meet regulatory threshold"
            },
            {
              "icon": "‚ö°",
              "name": "Accelerated Development",
              "strategy": "Use interim data for FDA Breakthrough Therapy Designation in PIK3CA wild-type",
              "rationale": "35% ORR exceeds FDA expectations for BTD in this population",
              "advantage": "Accelerated approval pathway, reduced Phase III requirements"
            }
          ]
        },
        "reasoning": {
          "title": "How does the system generate strategic recommendations?",
          "steps": [
            "**Multi-Scenario Optimization:** Evaluates 50+ protocol modification scenarios considering biomarker stratification and regulatory pathways",
            "**Risk-Benefit Quantification:** Models trade-offs between broader population vs. biomarker-selected approaches",
            "**Regulatory Pathway Simulation:** Uses FDA guidance to simulate approval pathways and success probability",
            "**Competitive Integration:** Factors in competitive CDK4/6 inhibitor timelines and market positioning",
            "**Economic Impact Modeling:** Calculates NPV impact of different strategies"
          ]
        },
        "feedback": {
          "question": "Which strategic approach resonates most with your development philosophy?",
          "options": [
            "Biomarker-driven pivot for stronger efficacy",
            "Dose optimization with broader population",
            "Accelerated regulatory strategy",
            "Need more risk-benefit analysis"
          ]
        }
      },
      
      {
        "stepNumber": 4,
        "title": "Expert Decision & Adaptive Monitoring",
        "expertDecision": {
          "type": "expert-decision",
          "speaker": "Dr. Rodriguez",
          "decision": "This analysis is incredibly helpful. I'm leaning toward the biomarker-driven pivot. The 35% ORR in PIK3CA wild-type patients is compelling, and the regulatory pathway advantages make sense. Let's model what the modified trial would look like and prepare for FDA discussion about the biomarker strategy.",
          "rationale": "Biomarker signal strength + regulatory advantage justifies timeline extension for stronger market position"
        },
        "systemUpdate": {
          "type": "system-analysis",
          "title": "Updated Trial Projections Based on Decision",
          "projections": [
            "**Modified Population:** PIK3CA wild-type HR+/HER2- metastatic breast cancer",
            "**Updated Sample Size:** 95 total patients (60 current + 35 additional)",  
            "**Revised Timeline:** 14 months total (6 additional months for targeted recruitment)",
            "**Statistical Power:** 90% power to detect 30% ORR vs. 15% historical control",
            "**Budget Impact:** +$3.2M for extended recruitment and biomarker screening",
            "**Commercial Advantage:** Clear differentiation, potentially faster approval"
          ]
        },
        "reasoning": {
          "title": "How does the system learn and adapt from this decision?",
          "steps": [
            "**Decision Impact Propagation:** Updates all trial projections based on biomarker-driven strategy",
            "**Recruitment Feasibility Modeling:** Assesses PIK3CA wild-type patient availability across site network",
            "**Regulatory Documentation Prep:** Generates FDA pre-submission meeting outline and BTD application components",
            "**Risk Mitigation Planning:** Identifies recruitment and biomarker testing logistics challenges",
            "**Organizational Learning:** Updates company biomarker development preferences for future trials"
          ]
        },
        "adaptiveMonitoring": {
          "title": "Real-Time Data Monitoring (Month 8 Update)",
          "alerts": [
            "**Recruitment Status:** 78/95 patients enrolled (ahead of timeline)",
            "**Efficacy Signal:** 38% ORR in PIK3CA wild-type population (exceeding projections)",
            "**Safety Profile:** Manageable toxicity at 450mg dose",
            "**Competitive Intel:** Competitor Phase III failure validates biomarker approach"
          ]
        },
        "feedback": {
          "question": "Which aspect of this data interpretation process would be most valuable for your organization?",
          "options": [
            "Statistical analysis and interpretation support",
            "Biomarker stratification guidance", 
            "Regulatory pathway optimization",
            "Competitive intelligence integration",
            "All of the above"
          ]
        }
      }
    ],
    
    "engagementTools": {
      "title": "Found this valuable? Take the next step:",
      "buttons": [
        {
          "text": "üìÑ Download Statistical Analysis Guide",
          "action": "download_statistical_guide"
        },
        {
          "text": "üì§ Share Biomarker Development Insights", 
          "action": "share_biomarker_insights"
        },
        {
          "text": "üöÄ Discuss Data Analysis Pilot",
          "action": "request_data_pilot"
        }
      ]
    }
  }
}